摘要
目的探讨乙型肝炎病毒(HBV)相关性肝癌人群接受程序性死亡受体1(PD-1)抑制剂联合靶向治疗后的HBV再激活发生率,及该治疗中HBV再激活和非再激活人群的预后差别。方法收集2019年1月至2021年6月在复旦大学附属中山医院厦门医院接受PD-1抑制剂联合靶向药物治疗的原发性肝癌患者进行回顾性分析。收集患者年龄、性别、肝功能状态、肝硬化情况、HBV DNA水平、甲胎蛋白、肿瘤分期、抗肿瘤方案及抗HBV方案、肿瘤治疗反应、无进展生存期(PFS)、总生存期(OS)等临床资料进行t检验、χ^(2)检验和Kaplan-Meier生存分析。结果共66例入组患者,其中17例发生HBV再激活,发生率为25.76%;其中3个月、6个月、1年、2年、3年的HBV再激活发生率分别为6.06%(4/66)、12.12%(8/66)、19.70%(13/66)、22.73%(15/66)、25.76%(17/66)。HBV再激活组和非HBV再激活组在年龄、性别、肝功能状态、肝硬化情况、HBV DNA水平、甲胎蛋白、肿瘤分期、抗肿瘤方案及抗HBV方案、客观缓解率(ORR)和疾病控制率(DCR)方面的差异均无统计学意义(均P>0.05)。但HBV再激活组的PFS和OS明显低于非HBV再激活组,分别为4.00个月vs 8.50个月(P=0.002)和12.90个月vs 19.77个月(P=0.014)。结论接受PD-1抑制剂联合靶向治疗的原发性肝癌患者有HBV再激活风险,且发生HBV再激活后的患者肿瘤进展和生存预后明显差于非HBV再激活者。
Objective To explore the incidence of hepatitis B virus(HBV)reactivation in the population with HBV associated liver cancer after receiving programmed death receptor 1(PD-1)inhibitors combined with targeted therapy,and the prognostic differences between HBV reactivation and non reactivation populations during this treatment.Methods A retrospective analysis was conducted on patients with primary liver cancer who received PD-1 inhibitor combined with targeted drugs treatment at the Zhongshan Hospital,Fudan University(Xiamen Branch)from January 2019 to June 2021.Clinical data such as age,sex,liver function status,cirrhosis,HBV DNA level,alpha fetoprotein,tumor stage,anti-tumor program and anti HBV program,tumor treatment response,progression free survival(PFS),and total survival(OS)were collected for t test,χ^(2) test and Kaplan-Meier survival analysis.Results A total of 66 enrolled patients were enrolled,of which 17 cases experienced HBV reactivation,with an incidence rate of 25.76%;The rates of HBV reactivation at 3 months,6 months,1 year,2 years,and 3 years were 6.06%(4/66),12.12%(8/66),19.70%(13/66),22.73%(15/66),and 25.76%(17/66),respectively.There was no significant difference between the HBV reactivation group and the non HBV reactivation group in age,sex,liver function status,cirrhosis,HBV DNA level,alpha fetoprotein,tumor stage,anti-tumor and anti HBV programs,objective response rate(ORR)and disease control rate(DCR)(all P>0.05).However,the PFS and OS of the HBV reactivation group were significantly lower than those of the non HBV reactivation group,at 4.00 months vs 8.50 months(P=0.002)and 12.90 months vs 19.77 months(P=0.014),respectively.Conclusions Patients with primary live cancer who receive PD-1 inhibitor combined with targeted therapy are at risk of HBV reactivation,and those who experience HBV reactivation have significantly poorer tumor progression and survival prognosis compared with non HBV reactivated patients.
作者
郑唐辉
张真真
陈国彬
张博恒
Zheng Tanghui;Zhang Zhenzhen;Chen Guobin;Zhang Boheng(Department of Hepatic Oncology,Zhongshan Hospital,Fudan University(Xiamen Branch),Xiamen 361009,China;Xiamen Clinical Research Center for Cancer Therapy,Xiamen 361009,China;The Liver Cancer Institute,Fudan University,Shanghai 200032,China;Key Laboratory for Carcinogenesis and Cancer Invasion,The Chinese Ministry of Education,Shanghai 200032,China;Center for Evidence-based Medicine,Fudan University,Shanghai 200032,China)
出处
《中国医师杂志》
CAS
2024年第4期484-488,共5页
Journal of Chinese Physician
基金
福建省自然科学基金项目(2022J011428)
厦门市科技计划指导性项目(3502Z20224ZD1082)。
关键词
肝肿瘤
乙型肝炎病毒
免疫检查点抑制剂
靶向治疗
再激活
Liver neoplasms
Hepatitis B virus
Immune checkpoint inhibitors
Targeted therapy
Reactivation
